Transoral robotic retropharyngeal lymph node dissection in a recurrent head and neck carcinoma

Head & Neck ◽  
2019 ◽  
Vol 41 (11) ◽  
pp. 4051-4053 ◽  
Author(s):  
Gerardo Petruzzi ◽  
Jacopo Zocchi ◽  
Silvia Moretto ◽  
Barbara Pichi ◽  
Giovanni Cristalli ◽  
...  
Keyword(s):  
Lymph Node ◽  
Head And Neck ◽  
Lymph Node Dissection ◽  
Head And Neck Carcinoma ◽  
Node Dissection ◽  
Retropharyngeal Lymph Node ◽  
Neck Carcinoma ◽  
Recurrent Head

Surgical or Radiosurgical Failures on Cervical Lymph Nodes in Treatment of Head and Neck Cancer

1984 ◽  
Vol 70 (3) ◽  
pp. 261-266
Author(s):  
Sante Basso-Ricci ◽  
Gianfranco Coopmans de Yoldi ◽  
Luca de Flaviis ◽  
Franco Milani ◽  
Gian Maria Danesini
Keyword(s):  
Lymph Node ◽  
Lymph Nodes ◽  
Head And Neck ◽  
Lymph Node Dissection ◽  
Radiation Treatment ◽  
Postoperative Radiotherapy ◽  
Head And Neck Carcinoma ◽  
Preoperative Radiation ◽  
Node Dissection ◽  
Cervical Lymph Nodes

From a series of 850 patients with head and neck carcinoma and subjected to lymph node dissection, 80 cases of recurrences in the neck have been collected. Postoperative radiotherapy was performed only in cases with metastatic extranodal spread. Of these recurrences, 56 occurred in the area of lymph node dissection, 7 were marginal and 17 were contralateral. The recurrences occurred prevalently in node-positive (N +) patients (70 of 80). The incidence of recurrences in the dissection area was 41.6 % (25 of 60) in cases with metastatic extranodal spread, despite postoperative radiotherapy. The incidence of recurrences in cases with clinically evident metastases at the time of dissection but without extranodal spread and not subjected to postoperative radiotherapy was relatively high (24.1 %, or 28 of 116). Since recurrences occurred, despite postoperative radiotherapy, in a relatively high percentage of cases with carcinoma of the oral floor and of the tongue (59.1 % and 50 %, respectively), it seems justifiable to perform preoperative radiation treatment in cases with clinically evident metastatic lymph nodes. As regards marginal recurrences, which all occurred in patients with carcinoma of the oral floor, it is considered sufficient to extend the surgical treatment to the subhyoid region. The high incidence of contralateral recurrences, which occurred mainly in patients with carcinoma of the larynx (13 of 17), shows the usefulness of radiation treatment of the contralateral region of the neck in these tumors, when dissection is limited to only one side of the neck.

Stereotactic radiosurgery for patients with recurrent head and neck carcinoma: Five years’ observation report.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. e16049-e16049
Author(s):  
Koji Kawaguchi
Keyword(s):  
Lymph Node ◽  
Head And Neck ◽  
Stereotactic Radiosurgery ◽  
Lymph Node Metastases ◽  
Head And Neck Carcinoma ◽  
Complete Response ◽  
Lymph Node Involvement ◽  
Neck Carcinoma ◽  
Node Metastases ◽  
Recurrent Head

e16049 Background: The aim of this study is to examine the effect of stereotactic radiosurgery (SRS) in the treatment of advanced, recurrent lesions for head and neck carcinoma both with and without lymph node involvement. Methods: Between April 2006 and July 2007, 22 patients (mean age 67 years) with advanced, recurrent head and neck carcinoma were treated with SRS by CyberKnife-II. All of the patients excepted one had biopsy confirmed disease prior to SRS. Patients included 3 rT2, 8 rT3, and 9 rT4; 8 of the patients had lymph node metastases. Marginal SRS doses were 20-42 Gy delivered in two to five fractions. Starting one month after SRS, all patients received S-1 oral chemotherapy for one year. Results: At an overall median follow-up of 64 months (range, 4-69 months), for the 14 locally recurrent patients without lymph node metastases, 9 patients (64.3%) had a complete response (CR), 1 patient (7.1%) had a partial response (PR), 1 patient (7.1%) had stable disease (SD), and 3 patients (21.4%) had progressive disease (PD). For the 8 patients with lymph node metastases, 1 patient with a single retropharyngeal (12.5%) had CR; the remaining 7 patients (87.5%) all progressed. Nine patients have died from their cancer. The overall 5-year survival for the patients with and without lymph node metastases was 12.5% and 78.6%, respectively. Conclusions: These results show the benefit of stereotactic radiosurgery salvage treatment for advanced, recurrent lesions, without lymph node metastases in previously irradiated head and neck cancer.

Permanent Implantation of Iodine-125 Seeds as a Salvage Therapy for Recurrent Head and Neck Carcinoma After Radiotherapy

2012 ◽  
Vol 30 (3) ◽  
pp. 236-242 ◽  
Author(s):  
Na Meng ◽  
Yu Liang Jiang ◽  
Jun Jie Wang ◽  
Wei Qiang Ran ◽  
Hui Shu Yuan ◽  
...  
Keyword(s):  
Head And Neck ◽  
Salvage Therapy ◽  
Head And Neck Carcinoma ◽  
Neck Carcinoma ◽  
Iodine 125 ◽  
Recurrent Head

Recurrence of Lymph Node Micrometastases After Radiotherapy for Head and Neck Carcinoma: A Propensity Score-matched Study

2021 ◽  
Vol 1 (3) ◽  
pp. 165-172
Author(s):  
YU SUZUKI ◽  
KEIICHI JINGU ◽  
EIICHI ISHIDA ◽  
TAKAKI MURATA ◽  
MASAKI KUBOZONO
Keyword(s):  
Lymph Node ◽  
Propensity Score ◽  
Head And Neck ◽  
Irradiation Dose ◽  
Concurrent Chemoradiotherapy ◽  
Head And Neck Carcinoma ◽  
Lymph Node Micrometastases ◽  
Neck Carcinoma ◽  
Matched Study ◽  
Observation Period

Background: The standard irradiation dose to the elective lymph node area (ELNA) in locally patients with advanced head and neck squamous cell carcinoma (LA-HNSCC) to control lymph node micrometastases (LN-MM) has not changed since it was empirically determined in the 1950s. We investigated the optimal irradiation dose for controlling LN-MM in ELNAs. Patients and Methods: The pattern of recurrence of LA-HNSCC was retrospectively evaluated in patients who underwent concurrent chemoradiotherapy with cisplatin or radiation therapy alone. Results: In total, 162 patients were enrolled. The median observation period was 34 months. No recurrence was found in ELNAs. After propensity score matching, a cisplatin dose of ≥200 mg/m2 yielded a significantly higher overall survival rate (p≤0.001) and locoregional control rate (p=0.034) than did a dose of <100 mg/m2. Conclusion: CCRT with a cisplatin dose of ≥200 mg/m2 can reduce the irradiation dose to 40-44 Gy at 2 Gy per fraction to control LN-MM.

Retropharyngeal Lymph Node Dissection

2011 ◽  
pp. 213-219
Author(s):  
James I. Cohen ◽  
Peter E. Andersen ◽  
Gary L. Clayman
Keyword(s):  
Lymph Node ◽  
Lymph Node Dissection ◽  
Node Dissection ◽  
Retropharyngeal Lymph Node
Sign in / Sign up

Export Citation Format

Share Document